Hadasit Bio-Holdings Ltd (HSITF)
USD 0.12
(0.0%)
USD 0.12
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.12 Million ILS | -47.25% |
| 2022 | 2.12 Million ILS | 181.54% |
| 2021 | -2.6 Million ILS | -47.15% |
| 2020 | -1.77 Million ILS | 1.88% |
| 2019 | -1.8 Million ILS | 88.95% |
| 2018 | -16.34 Million ILS | 6.77% |
| 2017 | -17.52 Million ILS | -92.48% |
| 2016 | -9.1 Million ILS | 83.42% |
| 2015 | -54.91 Million ILS | -1315.02% |
| 2014 | -3.88 Million ILS | 60.79% |
| 2013 | -9.89 Million ILS | 29.58% |
| 2012 | -14.05 Million ILS | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.65 Million ILS | 0.0% |
| 2024 Q1 | -1.65 Million ILS | -247.46% |
| 2023 Q1 | 924 Thousand ILS | -56.52% |
| 2023 Q4 | 1.12 Million ILS | 0.0% |
| 2023 FY | 1.12 Million ILS | -47.25% |
| 2023 Q3 | 1.12 Million ILS | 21.32% |
| 2023 Q2 | 924 Thousand ILS | 0.0% |
| 2022 Q2 | -2.19 Million ILS | 0.0% |
| 2022 FY | 2.12 Million ILS | 181.54% |
| 2022 Q4 | 2.12 Million ILS | 0.0% |
| 2022 Q3 | 2.12 Million ILS | 197.03% |
| 2022 Q1 | -2.19 Million ILS | 15.96% |
| 2021 FY | -2.6 Million ILS | -47.15% |
| 2021 Q4 | -2.6 Million ILS | 0.0% |
| 2021 Q2 | -4.06 Million ILS | 0.0% |
| 2021 Q3 | -2.6 Million ILS | 35.86% |
| 2021 Q1 | -4.06 Million ILS | -129.42% |
| 2020 FY | -1.77 Million ILS | 1.88% |
| 2020 Q2 | -746 Thousand ILS | 0.0% |
| 2020 Q3 | -1.77 Million ILS | -137.4% |
| 2020 Q4 | -1.77 Million ILS | 0.0% |
| 2020 Q1 | -746 Thousand ILS | 58.67% |
| 2019 Q3 | -1.8 Million ILS | 51.32% |
| 2019 Q4 | -1.8 Million ILS | 0.0% |
| 2019 Q1 | -3.7 Million ILS | 77.31% |
| 2019 FY | -1.8 Million ILS | 88.95% |
| 2019 Q2 | -3.7 Million ILS | 0.0% |
| 2018 Q1 | -20.95 Million ILS | -19.55% |
| 2018 FY | -16.34 Million ILS | 6.77% |
| 2018 Q3 | -16.34 Million ILS | 22.02% |
| 2018 Q2 | -20.95 Million ILS | 0.0% |
| 2018 Q4 | -16.34 Million ILS | 0.0% |
| 2017 FY | -17.52 Million ILS | -92.48% |
| 2017 Q1 | -9.73 Million ILS | -6.94% |
| 2017 Q2 | -9.73 Million ILS | 0.0% |
| 2017 Q3 | -17.8 Million ILS | -82.8% |
| 2017 Q4 | -17.52 Million ILS | 1.54% |
| 2016 Q4 | -9.1 Million ILS | 16.02% |
| 2016 FY | -9.1 Million ILS | 83.42% |
| 2016 Q3 | -10.84 Million ILS | 40.52% |
| 2016 Q2 | -18.23 Million ILS | 67.76% |
| 2016 Q1 | -56.54 Million ILS | -2.97% |
| 2015 Q1 | -3.32 Million ILS | 14.46% |
| 2015 Q4 | -54.91 Million ILS | -2434.24% |
| 2015 Q2 | -4.35 Million ILS | -31.23% |
| 2015 Q3 | -2.16 Million ILS | 50.26% |
| 2015 FY | -54.91 Million ILS | -1315.02% |
| 2014 FY | -3.88 Million ILS | 60.79% |
| 2014 Q3 | -7.84 Million ILS | 34.21% |
| 2014 Q2 | -11.91 Million ILS | -4.79% |
| 2014 Q1 | -11.37 Million ILS | -14.89% |
| 2014 Q4 | -3.88 Million ILS | 50.5% |
| 2013 Q1 | -11.98 Million ILS | 14.71% |
| 2013 Q4 | -9.89 Million ILS | 34.0% |
| 2013 Q3 | -14.99 Million ILS | -56.41% |
| 2013 FY | -9.89 Million ILS | 29.58% |
| 2013 Q2 | -9.58 Million ILS | 20.02% |
| 2012 Q4 | -14.05 Million ILS | 0.0% |
| 2012 FY | -14.05 Million ILS | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 266.546% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 7.652% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -11.242% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 97.38% |
| GB Sciences, Inc. | 1.74 Million USD | 35.844% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 112.681% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 12194.938% |
| Skye Bioscience, Inc. | -5.72 Million USD | 119.593% |
| Zenith Capital Corp. | 10.06 Thousand USD | -11038.712% |
| Agentix Corp. | 37.63 Thousand USD | -2878.927% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 80.154% |
| Biomind Labs Inc. | 711.4 Thousand USD | -57.576% |
| ContraFect Corporation | -6.02 Million USD | 118.603% |
| CSL Limited | 10.52 Billion USD | 99.989% |
| CytoDyn Inc. | 20.26 Million USD | 94.467% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -211.64% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -80.12% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 97.419% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 5592.944% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -20.903% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -76.489% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 117.781% |
| SQZ Biotechnologies Company | -36.23 Million USD | 103.093% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -30.312% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 92.888% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 50.005% |
| Mesoblast Limited | 55.85 Million USD | 97.993% |
| Marizyme, Inc. | 18.56 Million USD | 93.963% |
| Genus plc | 190.6 Million USD | 99.412% |
| Pharming Group N.V. | 109.8 Million USD | 98.979% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -64.853% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 2.98% |
| IMV Inc. | 7.67 Million USD | 85.386% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 79.625% |
| MultiCell Technologies, Inc. | 90.04 USD | -1244902.221% |
| ONE Bio Corp. | 9.04 Million USD | 87.6% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 91.341% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 96.331% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 43.933% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 91.247% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -701.837% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -5542.523% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 709.942% |
| Enzolytics Inc. | 981.65 Thousand USD | -14.195% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.055% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 102.384% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 84.146% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.106% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 72.778% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -178.961% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 53.018% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -581.422% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 6219.664% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 49.862% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -732.597% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 252.729% |
| Helix BioMedix, Inc. | -2.57 Million USD | 143.618% |
| EV Biologics, Inc. | 1.36 Million USD | 18.054% |
| Q BioMed Inc. | 4.06 Million USD | 72.389% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 94.471% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.149% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 74.933% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 49.091% |
| HST Global, Inc. | 96.79 Thousand USD | -1058.142% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 85672.519% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -443.602% |
| Halberd Corporation | 144.72 Thousand USD | -674.594% |
| Resverlogix Corp. | 6.45 Million USD | 82.623% |
| Cell Source, Inc. | 9.23 Million USD | 87.857% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 58.614% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | 118.99% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -459.292% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 48.542% |
| Kadimastem Ltd | -253.1 Thousand USD | 542.904% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -724.331% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -457.008% |
| LadRx Corporation | -2.03 Million USD | 155.046% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -76.489% |
| Affymax, Inc. | -5.59 Million USD | 120.029% |
| Itoco Inc. | 228.3 Thousand USD | -391.01% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 77.386% |
| Mobile Lads Corp. | 484.23 Thousand USD | -131.501% |
| International Stem Cell Corporation | 2.59 Million USD | 56.718% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | 40.966% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 173361.206% |
| Qrons Inc. | 351.42 Thousand USD | -218.985% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 85.453% |
| SYBLEU INC | 473.71 Thousand USD | -136.641% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 549.083% |
| Rebus Holdings, Inc. | 305 Thousand USD | -267.541% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 74.849% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1696.1% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 48.599% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 67.356% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 86.893% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -45.093% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 189.68% |
| Neutra Corp. | 52.18 Thousand USD | -2048.045% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 145.038% |
| PureTech Health plc | -167.19 Million USD | 100.67% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 557.723% |
| IXICO plc | -4.44 Million USD | 125.222% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 91.52% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 97.956% |
| CSL Limited | 10.52 Billion USD | 99.989% |
| Cellectis S.A. | -43.81 Million USD | 102.558% |